Show simple item record

dc.contributor.authorMorgado-Palacin, Isabel
dc.contributor.authorDay, Amanda
dc.contributor.authorMurga, Matilde 
dc.contributor.authorLafarga, Vanesa 
dc.contributor.authorAnton, Marta Elena
dc.contributor.authorTubbs, Anthony
dc.contributor.authorChen, Hua Tang
dc.contributor.authorErgan, Aysegul
dc.contributor.authorAnderson, Rhonda
dc.contributor.authorBhandoola, Avinash
dc.contributor.authorPike, Kurt G
dc.contributor.authorBarlaam, Bernard
dc.contributor.authorCadogan, Elaine
dc.contributor.authorWang, Xi
dc.contributor.authorPierce, Andrew J
dc.contributor.authorHubbard, Chad
dc.contributor.authorArmstrong, Scott A
dc.contributor.authorNussenzweig, André
dc.contributor.authorFernandez-Capetillo, Oscar 
dc.date.accessioned2024-02-09T11:25:30Z
dc.date.available2024-02-09T11:25:30Z
dc.date.issued2016-09-13
dc.identifier.citationSci Signal . 2016;9(445):ra91. des_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17690
dc.description.abstractAmong the various subtypes of acute myeloid leukemia (AML), those with chromosomal rearrangements of the MLL oncogene (AML-MLL) have a poor prognosis. AML-MLL tumor cells are resistant to current genotoxic therapies because of an attenuated response by p53, a protein that induces cell cycle arrest and apoptosis in response to DNA damage. In addition to chemicals that damage DNA, efforts have focused on targeting DNA repair enzymes as a general chemotherapeutic approach to cancer treatment. Here, we found that inhibition of the kinase ATR, which is the primary sensor of DNA replication stress, induced chromosomal breakage and death of mouse AML(MLL) cells (with an MLL-ENL fusion and a constitutively active N-RAS independently of p53. Moreover, ATR inhibition as a single agent exhibited antitumoral activity, both reducing tumor burden after establishment and preventing tumors from growing, in an immunocompetent allograft mouse model of AML(MLL) and in xenografts of a human AML-MLL cell line. We also found that inhibition of ATM, a kinase that senses DNA double-strand breaks, also promoted the survival of the AML(MLL) mice. Collectively, these data indicated that ATR or ATM inhibition represent potential therapeutic strategies for the treatment of AML, especially MLL-driven leukemias.es_ES
dc.description.sponsorshipWork in O.F.-C. laboratory was supported by Fundacion Botin, by Banco Santander through its Santander Universities Global Division, and by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2014-57791-REDC and SVP-2013-068072), Fundacio La Marato de TV3, the Howard Hughes Medical Institute, and the European Research Council (ERC-617840). The A.N. laboratory was supported by the Intramural Research Program of the NIH, the National Cancer Institute (NCI), the Center for Cancer Research, an Ellison Medical Foundation Senior Scholar in Aging, and the Alex Lemonade Stand Foundation Award.es_ES
dc.language.isoenges_ES
dc.publisherAmerican Association for the Advancement of Science (AAAS) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAtaxia Telangiectasia Mutated Proteins es_ES
dc.subject.meshGene Rearrangement es_ES
dc.subject.meshHistone-Lysine N-Methyltransferase es_ES
dc.subject.meshLeukemia, Myeloid, Acute es_ES
dc.subject.meshMyeloid-Lymphoid Leukemia Protein es_ES
dc.subject.meshNeoplasms, Experimental es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMice es_ES
dc.subject.meshXenograft Model Antitumor Assays es_ES
dc.titleTargeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID27625305es_ES
dc.format.volume9es_ES
dc.format.number445es_ES
dc.format.pagera91es_ES
dc.identifier.doi10.1126/scisignal.aad8243es_ES
dc.contributor.funderFundación La Marató TV3 es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderHoward Hughes Medical Institute es_ES
dc.contributor.funderUnited States Department of Health and Human Services es_ES
dc.contributor.funderLawrence Ellison Foundationes_ES
dc.contributor.funderBanco Santander es_ES
dc.contributor.funderBotín Foundation es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1937-9145es_ES
dc.relation.publisherversionhttps://doi.org/10.1126/scisignal.aad8243.es_ES
dc.identifier.journalScience signalinges_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Inestabilidad Genómicaes_ES
dc.identifier.pmchttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066844/
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/617840/EUes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/SAF2014-57791-REDCes_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/SVP-2013-068072es_ES


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional